— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in…
Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001).In…
ICSI fertilization rates and subsequent pregnancy rates were not different between men with normal or low Cap-ScoresMen with low Cap-Scores…
New study demonstrates the value of using the Cap-Score Test to assess the fertilizing ability in men of all ages…
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and…
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm…
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for…
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in…
- Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal…
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based…